NVST logo

ENVISTA HOLDINGS CORP

NVSTNYSE
πŸ† #1451 by market capEarnings Nov 4 Β· PostUS Equity
$24.62β–² $0.68 (+2.84%)
πŸŒ™ After hours$24.61β–Ό 0.04%Regular close Β· extended-hours price shown
πŸ””
Track NVST
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.8%
7dβ–² 2.7%
14dβ–² 4.8%
30dβ–² 5.4%
ytdβ–² 13.4%
1yβ–² 23.2%
🏦Market Cap
$3.95B
Small Cap
πŸ“ˆRevenue Growth (YoY)
8.3%
Slowing
πŸ“ŠGross Margin
55.5%
Healthy
πŸ’΅FCF Margin
8.1%
Moderate
βš–οΈP/S Ratio
1.3x
Cheap
Otter Score
76
Strong

Trading Snapshot

Day Range
$24.03 – $24.68
52-Week Range
$18.77 – $30.42
Volume (shares)
2,386,792
Avg Volume (shares)
β€”
Shares Outstanding
160.6M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$2.72B
Last Q Revenue
$731M
P/E Ratio
40.6
P/S Ratio
1.3x
EPS (TTM)
$0.59
Dividend Yield
0.00%
Dilution (1yr)
βˆ’3.6%
NVST logo

ENVISTA HOLDINGS CORP

NVST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.7Bβ–² +8.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
55.0%β–Ό βˆ’0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$226Mβ–Ό βˆ’121.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$230Mβ–Ό βˆ’23.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
166.0Mβ–Ό βˆ’3.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$386Mβ–² +$93M YoY
StockOtter Β· stockotter.space

About ENVISTA HOLDINGS CORP

Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100

Analyst Ratings

β“˜
Consensus
Buy
21 analysts
Strong Buy7
Buy6
Hold8
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment ResearchΒ·1d ago

Envista Q3 Earnings Ahead: Product Innovation to Drive Growth

Envista NVST is scheduled to release third-quarter 2026 results on Nov. 4, after the closing bell.

Zacks Investment ResearchΒ·1d ago

Envista (NVST) Earnings Expected to Grow: Should You Buy?

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWireΒ·2d ago

Envista Announces Release of 2025 Sustainability Report

BREA, Calif., Oct. 27, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced the publication of its 2025 Sustainability Report.

Defense WorldΒ·11d ago

Reviewing MariMed (OTCMKTS:MRMD) and Envista (NYSE:NVST)

Envista (NYSE: NVST - Get Free Report) and MariMed (OTCMKTS:MRMD - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their ea

Defense WorldΒ·18d ago

Envista Holdings Corporation (NYSE:NVST) Stock Rated β€œHold” by Wall Street Brokerages

Envista Holdings Corporation (NYSE: NVST - Get Free Report) has received a consensus rating of "Hold" from the seventeen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Ten research analy

Zacks Investment ResearchΒ·20d ago

Envista (NVST) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.